Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Haha, I knew news was coming today. No converting, there had to be a reason. I would imagine that this tanks but SOMEONE is going to interpret this as good news.
GENTA NEWS - AGENDA RESULTS DELAYED UNTIL MAY!!!
News for 'GNTA' - (Genta Updates Guidance on Survival Results From Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma)
Apr 21, 2011 (GlobeNewswire via COMTEX) --
-- Final Top-Line Survival Results Expected in May 2011
-- AGENDA Abstract Accepted for Presentation at ASCO
BERKELEY HEIGHTS, N.J., April 21, 2011 (GLOBE NEWSWIRE) -- Genta Incorporated
(OTCBB:GNTA) today updated its formal guidance for release of results from its
Phase 3, randomized, controlled trial of Genasense(R) (oblimersen sodium)
Injection in patients with advanced melanoma, also known as the AGENDA trial.
After completion of final data collection, transfer and locking of the database,
and statistical analysis, the Company expects to release a "top-line" statement
regarding the result for overall survival in May 2011. The data collection
process for this double-blind trial has not yet been completed.
A more extended analysis of efficacy and safety from AGENDA will be presented at
the annual meeting of the American Society of Clinical Oncology (ASCO) in June
2011. A provisional abstract regarding AGENDA -- which has indicated only that
results for the late endpoints of overall survival and durable response would be
available -- has been accepted for presentation at the meeting.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product
portfolio that is focused on delivering innovative products for the treatment of
patients with cancer. The Company is developing tesetaxel, a novel, orally
absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel.
As the leading oral taxane in clinical development, tesetaxel has been evaluated
in a broad program of completed or ongoing Phase 2a/Phase 2b clinical trials.
The Company has announced that gastric (stomach) cancer will be the lead
indication for Phase 3 registration studies. Genasense(R) (oblimersen sodium)
Injection is a modified DNA-based antisense drug that may enhance the
effectiveness of anticancer therapy. Genta has completed enrollment in a
randomized, double-blind Phase 3 study of Genasense(R) in patients with advanced
melanoma, known as "AGENDA". Survival data from AGENDA are projected to be
available in the second quarter of 2011. Genta is exclusively marketing
Ganite(R) (gallium nitrate injection) in the U.S., which is indicated for
treatment of symptomatic patients with cancer-related hypercalcemia that is
resistant to hydration. The Company has developed proprietary oral formulations
of the active ingredient in Ganite(R) that are being evaluated as potential
treatments for diseases associated with accelerated bone loss. Ganite(R) and
Genasense(R) are available on a "named-patient" basis in countries outside the
United States. For more information about Genta, please visit our website at:
www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with respect to
business conducted by Genta Incorporated. By their nature, forward-looking
statements and forecasts involve risks and uncertainties because they relate to
events and depend on circumstances that will occur in the future. Such
forward-looking statements include those that express plan, anticipation,
intent, contingency, goals, targets, or future developments and/or otherwise are
not statements of historical fact. The words "potentially", "anticipate",
"could", "calls for", and similar expressions also identify forward-looking
statements. The Company does not undertake to update any forward-looking
statements. Factors that could affect actual results include, without
limitation, risks associated with:
-- the Company's ability to obtain necessary regulatory approval for its
product candidates from regulatory agencies, such as the U.S. Food and
Drug Administration and the European Medicines Agency;
-- the safety and efficacy of the Company's products or product candidates;
-- the timing of commencement and completion of any clinical trials;
-- the Company's assessment of its clinical trials;
-- the Company's ability to develop, manufacture, license, or sell its
products or product candidates;
-- the Company's ability to enter into and successfully execute any license
and collaborative agreements;
-- the adequacy of the Company's capital resources and cash flow
projections, the Company's ability to obtain sufficient financing to
maintain the Company's planned operations, or the risk of bankruptcy;
-- the adequacy of the Company's patents and proprietary rights;
-- the impact of litigation that has been brought against the Company; and
-- the other risks described under Certain Risks and Uncertainties Related
to the Company's Business, as contained in the Company's Annual Report
on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments
to differ materially. For a discussion of those risks and uncertainties, please
see the Company's Annual Report on Form 10-K for 2010 and its most recent
quarterly report on Form 10-Q.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Genta Incorporated
By Staff
CONTACT: CONTACT: Genta Investor Relations
info@genta.com
Media Contact
908-286-3980
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
-0-
INDUSTRY KEYWORD: Biotechnology
SUBJECT CODE: MEDICAL
HEALTH
Product Services Announcement
Source: Comtex Wall Street News
Compliments of Scottrade.com
http://ih.advfn.com/p.php?pid=nmona&article=47394981
you are definitely right...and hey sakata, its been a while. i ended up buying that steve nison candlestick book you recommended for me. awesome book, love charting now more than anything. thanks again!
Did they stop converting? Volume all dried up.
i agree!
Currently, the price is still trending upwards on the short-term trendline. I do think it has enough strength to bust through .0017-.0020 resistance. I have seen accumulation, its almost as high as it was in november.
But about that november run, that only occured because they actually put out a 10Q that day. two weeks later they filed for exemption from filing anymore...they are in essence, a shell. I hope that something comes from this. The only other time the trendline of highs was broken was that day in november. the .0014 close yesterday was the first close sense then above the resistance trendline of decending highs. despite today's throwback, i still think it has a great chance of success, especially with a close tomorrow of .0013 or higher, preferrably .0014, to set up the weekly chart. big resistance .0017 - .002 like i said, but should be rather blue skies from there.
thank you for your information, you are the most "real" of the posters here that I have seen thus far.
you keep saying a bunch of radars...no one is talking about UNVC...there has only been ONE new boardmark since I started following this 3 days ago...and no one is really talking about it except for you and ash and a couple others.
where are these radars that you are talking about? what "private radars" are you looking at that we don't know about? talk about koolaid...
Listen, I don't think you understand what I'm talking about.
Firstly, few = 3 and november 2010 was 5 months ago, where they put out a filing that allows them to not file anymore and still be a stock.
Secondly, I didn't say anything about the website update being negative, I'm glad that they have done that.
Thirdly, who said I'm here for a flip? I'm in at .0013 I didnt say that I'm going to sell at .0026 did I? I'm saying that the only reason people are buying right now is because of VOLUME...and VOLUME is a technical indicator.
People aren't buying based on fundamentals, because no fundamentals have happened. There is no Press Release that has come out where people go "Oh my, this is great news, I'm going to buy"
We are buying in theory "AHEAD OF the news"...thus we are buying based on VOLUME which is a TECHNICAL INDICATOR.
Because it didn't look like it was going to break those resistances, and I'm sick of waiting for a bunch of liars to post financials, make a website, show contracts, etc. They never deliver ANYTHING for shareholders. I hope for your sake, that they do.
Wizdom7:Last filing Nov2010...Dont lie...what are you talking about?
http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=UNVC&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
and when I say purely technical, i mean that the only reason that anyone could be buying is because of the TECHNICAL INDICATORS (VOLUME)....NOTHING has happened with this stock in months, there has been no FUNDAMENTAL news. no filings, nothing. the only things that have happened to spark any interest is something technical.
Like always, I am hoping that the technical reasons for buying prove to show something fundamental that will make it go up a ton. That's the whole point of why anyone is buying down here. "Hmm, where is this volume and buying pressure coming from? Lets buy and see if the company puts out an update."
Dont act like I don't know what I'm talking about.
can you please post a screenshot of L2?
oh it's purely technical -- weekly MACD has a great chance of a zero cross with a break of .0017 and further .0020. If that happens it should go to .005 at least. Maybe for just a day.
jmbar, your expertise are very welcome here, but note that i don't think a single person on this board is investing in this...they are all buying in to trade and sell off of a quick pump. you are probably spot on about the future of this company -- but its something that is meaningless to this trade (except for sharing the fact to SELL AS SOON AS YOU HAVE PROFITS!)
=)
don't know, i actually sold today to be honest. i still think this will go over a penny if they ever put out financials
yeah, i'm hoping that this can break the .0017 - .0020 resistance
okay, well i was the .0013 that you posted about earlier...i like the potential here with this one, the SS is remarkable if still 181M or even under 500M
can you get an L2 shot before EOD?
hey brotha! LSBG:.0023 OPTZ:.0006 UNVC:.0008 DKSC:.0012 CGSYQ:.0023
my watchlist! hope you've been well!
big resistance .0070 - .0080
if we make it to.0040s...then maybe we retry .01?
thinking of throwing a very VERY small amount of money at this..like 200$. I have lost $2K in genta and i would love to try to get some of it back on a revenge trade.
Something brewing here for sure IMO.. volume came in a bit friday
Smitter isn't questioning the selling. How would a 1:1000 help? It's 1:10000 anyways, when the share count is cut by 10000, so is YOURS.
There was always writing in SEC fillings that would have this go past 6 Bil OS beginning heavily at the start of 2011, and the increase 100,000,000,000 A/S just makes it sound like if Overall Survival doesn't allow them to sell Genasense (INCREIDBLE longshot)...then they are going to sign new financing that will go close to maxing out 100B outstanidng shares.
With two 1:100 reverse splits approved, that means 1:10000, which makes 100,000,000,000 shares turn into a cool 10 Million Outstanding again...
Now how do you like that for a rinse, repeat, make tons of cash selling converted shares and shorting the stock on the side? Ray is a rich man, brilliant in terms of cancer and making money, and probably THE most IMMORAL human being that I have EVER seen in my entire life.
What are you talking about? They have billions of shares to dilute, they are getting paid handsomely for all of this. There is nothing wrong with Genta in terms of making the officers of the company money. They make BOATLOADS of money EVERY year taking the stock down. There are clauses in the SEC filings that allow them to short the stock as well! What don't you get?
I'm interested in seeing Overall Survival and think there will be a significant run before that after this bottoms out in february.
Also, looks like Watson wants out of the life of crime, eh?
Hey everyone, with a few good closes we look poised to start a move here...maybe news is finally on its way. I'd like to see .0054 or higher for tomorrow, but that is asking alot. sad thing is the move may top out around a penny. I'm still holding my shares from .015 :(
I mean what else could their next news be? They have now had time to let all of these last few PRs materialize...I don't know...I am going to give them a call soon, maybe next week or I may wait until after the holidays.
i disagree with trip zeros
soon i think they will release financials
i will be applying to be the new moderator
looks like we lost a moderator
So when's the vote for 100 BILLION Authorized Shares?
WOW .0001... truly never thought i'd see the day
We are at .0003 now, still think its a good idea? I TOLD YOU SO
One more trading day after today is over and then it's Black Friday. You still need 1000% gains from the current price of .0004. Somehow I don't think you'll be here to say "I Told ya so!!!"
So who thinks the PR will say: IDCN CEO Jeffrey Bruhjell Attends Gala Film Festival
JRB deserves to be investigated, he is a criminal IMO. Telling IR to post lies about your company is a crime.